<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35348419</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases.</ArticleTitle>
        <Pagination>
          <StartPage>700</StartPage>
          <EndPage>707</EndPage>
          <MedlinePgn>700-707</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2022.2044862</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="UNASSIGNED">Resistance to BCR-ABL tyrosine kinase inhibitor (TKI) is the cause of treatment failure in blast phase chronic myeloid leukaemia (BP-CML). Agents that act synergistically with BCR-ABL TKI are required to improve response.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This work investigated the effects of stachydrine in CML.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">CML cells were treated with control or stachydrine at 20, 40 and 80 µM. Proliferation and apoptosis were examined after 72 h treatment. Combination studies were performed in four groups: control, TKI, stachydrine and the combination of stachydrine and TKI. Immunoblotting analysis was performed in CML cells after 24 h treatment.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Stachydrine inhibited K562 (IC<sub>50</sub> 61 µM), KCL22 (IC<sub>50</sub> 141 µM), LAMA84 (IC<sub>50</sub> 86 µM), Ba/F3 T315I (IC<sub>50</sub> 26 µM), Ba/F3 WT (IC<sub>50</sub> 22 µM) and KU812 (IC<sub>50</sub> 35 µM) proliferation, and induced apoptosis in these CML cell lines. Stachydrine significantly induced apoptosis, inhibited colony formation and self-renewal in BP-CML CD34<sup>+</sup> cells. The combination index of stachydrine and TKI combination was &lt;1. Compared to TKI alone, the combination of stachydrine and TKI significantly induced more apoptosis and decreased colony formation in BP-CML CD34<sup>+</sup> cells. Stachydrine decreased phosphorylation levels of multiple receptor tyrosine kinases in CML cells.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="UNASSIGNED">Our study is the first to demonstrate (1) the anticancer activity of stachydrine on primary patient cancer cells; (2) the inhibitory effects of stachydrine on cancer stem cells; (3) the synergism between stachydrine and other anticancer drugs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Ruixin</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Traditional Chinese Medicine, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Division, Hospital of Huazhong Agricultural University, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Dandan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rehabilitation Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Traditional Chinese Medicine, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>42HK56048U</RegistryNumber>
          <NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9DLQ4CIU6V</RegistryNumber>
          <NameOfSubstance UI="D011392">Proline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S1L688345C</RegistryNumber>
          <NameOfSubstance UI="C003342">stachydrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001752" MajorTopicYN="Y">Blast Crisis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015464" MajorTopicYN="Y">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Leukaemia</Keyword>
        <Keyword MajorTopicYN="N">synergy</Keyword>
        <Keyword MajorTopicYN="N">traditional Chinese medicine</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>12</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35348419</ArticleId>
        <ArticleId IdType="pmc">PMC8967197</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2022.2044862</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Agarwal S, Kazi JU, Ronnstrand L.. 
2013. Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation. J Biol Chem. 288(31):22460–22468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3829335</ArticleId>
            <ArticleId IdType="pubmed">23803604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R.. 
2001. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 98(13):7319–7324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC34666</ArticleId>
            <ArticleId IdType="pubmed">11404481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carra G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A.. 
2016. The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive leukemias. Oncotarget. 7(40):66287–66298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5323234</ArticleId>
            <ArticleId IdType="pubmed">27563822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandramohan Reddy T, Bharat Reddy D, Aparna A, Arunasree KM, Gupta G, Achari C, Reddy GV, Lakshmipathi V, Subramanyam A, Reddanna P.. 
2012. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation. Toxicol In Vitro. 26(3):396–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22245431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen M, Yang D, Hu X, Jiang G, Li T, Ouyang Z, Deng J.. 
2021. Stachydrine hydrochloride inhibits osteoclastogenesis by regulating the NF-κB and p38 signaling pathways to alleviate postmenopausal osteoporosis. Biochem Biophys Res Commun. 542:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33482468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng F, Zhou Y, Wang M, Guo C, Cao Z, Zhang R, Peng C.. 
2020. A review of pharmacological and pharmacokinetic properties of stachydrine. Pharmacol Res. 155:104755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32173585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC.
2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70(2):440–446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu S, Holtz M, Gupta M, Bhatia R.. 
2004. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood. 103(8):3167–3174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15070699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ.. 
2011. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 121(1):396–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3007128</ArticleId>
            <ArticleId IdType="pubmed">21157039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu R, Zhang M, Meng H, Xu D, Xie Y.. 
2018. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition. Biomed Pharmacother. 105:491–497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29883944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo W, Zhang C, Liao YL, Lv R, Wei HC.. 
2012. Effect of Leonurus stachydrine on myocardial cell hypertrophy. Zhong Yao Cai. 35(6):940–943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23236831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiwase DK, Yeung DT, White DL.. 
2011. Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Rev Hematol. 4(3):285–299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21668394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, Saglio G, Gale RP.. 
2019. Chronic myeloid leukemia stem cells. Leukemia. 33(7):1543–1556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6755964</ArticleId>
            <ArticleId IdType="pubmed">31127148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Jiang Y, Chen Y.. 
2017. Predicting drug combination index and simulating the network-regulation dynamics by mathematical modeling of drug-targeted EGFR-ERK signaling pathway. Sci Rep. 7:40752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5244366</ArticleId>
            <ArticleId IdType="pubmed">28102344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isozaki Y, Hoshino I, Akutsu Y, Hanari N, Mori M, Nishimori T, Murakami K, Akanuma N, Toyozumi T, Takahashi M, et al. . 
2014. Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map. Oncology. 87(6):351–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25195536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Rosee P, Holm-Eriksen S, Konig H, Hartel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, et al. . 
2008. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph + acute lymphoblastic leukemia patients treated with nilotinib. Haematologica. 93(5):765–769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18367481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Wei S, Zou Q, Luo Y.. 
2018. Stachydrine suppresses viability &amp; migration of astrocytoma cells via CXCR4/ERK &amp; CXCR4/Akt pathway activity. Future Oncol. 14(15):1443–1459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29873242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, Dufva IH, Kim DW, Cortes J, Mauro MJ, et al. . 
2013. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 98(10):1510–1516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3789454</ArticleId>
            <ArticleId IdType="pubmed">23716543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perrotti D, Jamieson C, Goldman J, Skorski T.. 
2010. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 120(7):2254–2264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898591</ArticleId>
            <ArticleId IdType="pubmed">20592475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan AN, Hua TN, Kim MK, Vo VT, Choi JW, Kim HW, Rho JK, Kim KW, Jeong Y.. 
2016. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget. 7(34):54702–54713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5342374</ArticleId>
            <ArticleId IdType="pubmed">27419630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rathee P, Rathee D, Rathee D, Rathee S.. 
2012. In vitro anticancer activity of stachydrine isolated from Capparis decidua on prostate cancer cell lines. Nat Prod Res. 26(18):1737–1740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21988653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren R.
2005. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 5(3):172–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15719031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawyers CL.
1999. Chronic myeloid leukemia. N Engl J Med. 340(17):1330–1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10219069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang X, Pan H, Wang X, He H, Li M.. 
2014. Leonurus japonicus Houtt.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 152(1):14–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24412548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G.. 
2018. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 17(1):49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817796</ArticleId>
            <ArticleId IdType="pubmed">29455643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Shu ZJ, Wang Y, Peng W.. 
2017. Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathways. Am J Transl Res. 9(4):1834–1844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5411931</ArticleId>
            <ArticleId IdType="pubmed">28469788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang Y, Guo Z, Zhu P, Chen J, Huang Y.. 
2019. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med. 8(5):1958–1975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6536969</ArticleId>
            <ArticleId IdType="pubmed">30945475</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
